Bicycle Therapeutics Stock News

Shares of Bicycle Therapeutics have risen by 68% over the past 12 months and 252% over the past 3 years.

Analysts have provided the following ratings for Bicycle Therapeutics (NASDAQ:BCYC) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 2 1

Analysts have provided the following ratings for Bicycle Therapeutics (NASDAQ: BCYC ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 2 1 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 1 0 0 2M Ago 0 0 0 0 0 3M Ago 1 1 0 0 0 In the last 3 months, 4 analysts have offered 12-month price targets for Bicycle Therapeutics. The company has an average price target of $71.25 with a high of $85.00 and a low of $60.00. Below is a summary of how these 4 analysts rated Bicycle Therapeutics over the past 3 months. The greater the number of bullish ratings, … Full story available on Benzinga.com

Bicycle Therapeutics (NASDAQ: BCYC ) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Bicycle Therapeutics missed estimated earnings by 3.28%, reporting an EPS of … Full story available on Benzinga.com

Bicycle Therapeutics Earnings, Revenue Miss in Q1

Bicycle Therapeutics press release (BCYC): Q4 GAAP EPS of -$0.63 beats by $0.01.Revenue of $3.77M (-2.1% Y/Y) misses by $1.11M.

- Continued clinical progress across pipeline of Bicycle Toxin Conjugates® and Bicycle tumor-targeted immune cell agonists - Cash of $438.7 million at December 31, 2021 expected to provide… | March 1, 2022

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided recent corporate updates. “We are encouraged by the progress we continue to make across our oncology pipeline,” said Kevin Lee, Ph.D., Chief Executive Office

BT8009 test results conformed to preliminary data suggesting it to be an effective treatment for tumors. BT7480 is currently advancing its phase I clinical trials, and CEO Dr. Kevin Lee said he is ple

Upgrades According to Mizuho, the prior rating for Murphy Oil Corp (NYSE:MUR) was changed from Neutral to Buy. In the fourth quarter, Murphy Oil showed an EPS of $0.40, compared to $0.09 from the yea

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022 at 9:20 a.m. ET. The conference will be held in a virtual meeting format. A live webcast of the fireside chat will b

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycl

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double.

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double